All In Biotech

Drug Trial Radar · NCT07251309

A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Dec 23, 2024

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.

Conditions

  • Hyperkalemia

Interventions

  • WS016Drug

    WS016 (12g), oral, three times daily for 48 hours, for a total of six doses.

  • PlaceboDrug

    Placebo, oral, three times daily for 48 hours, for a total of six doses.

  • WS016Drug

    WS016 (6g, 12g or 18g), oral, once daily for 28 consecutive days.

  • PlaceboDrug

    Placebo, oral, once daily for 28 consecutive days.

  • WS016Drug

    WS016, oral, once daily for 11 months, starting at a dose of 12g with subsequent dose adjustments based on serum potassium levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean serum potassium level during maintenance phase Days 8-29Time frame: Maintenance phase Days 8-29

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site 02

    Bengbu, Anhui, China · Recruiting

  • Investigator Site 03

    Wuhu, Anhui, China · Recruiting

  • Investigator Site 48

    Chongqing, Chongqing Municipality, China · Recruiting

  • Investigator Site 04

    Xiamen, Fujian, China · Recruiting

  • Investigator Site 05

    Lanzhou, Gansu, China · Recruiting

  • Investigator Site 07

    Guangzhou, Guangdong, China · Recruiting

  • Investigator Site 06

    Zhanjiang, Guangdong, China · Recruiting

  • Investigator Site 08

    Huizhou, Guangxi, China · Recruiting

  • Investigator Site 09

    Nanning, Guangxi, China · Recruiting

  • Investigator Site 10

    Nanning, Guangxi, China · Recruiting

  • Investigator Site 11

    Guiyang, Guizhou, China · Recruiting

  • Investigator Site 12

    Haikou, Hainan, China · Recruiting

  • Investigator Site 13

    Shijiazhuang, Hebei, China · Recruiting

  • Investigator Site 18

    Daqing, Heilongjiang, China · Recruiting

  • Investigator Site 15

    Nanyang, Henan, China · Recruiting

  • Investigator Site 16

    Nanyang, Henan, China · Recruiting

  • Investigator Site 14

    Puyang, Henan, China · Recruiting

  • Investigator Site 25

    Xinxiang, Henan, China · Recruiting

  • Investigator Site 21

    Huangshi, Hubei, China · Recruiting

  • Investigator Site 20

    Shiyan, Hubei, China · Recruiting

  • Investigator Site 19

    Wuhan, Hubei, China · Recruiting

  • Investigator Site 22

    Wuhan, Hubei, China · Recruiting

  • Investigator Site 24

    Hengyang, Hunan, China · Recruiting

  • Investigator Site 17

    Yueyang, Hunan, China · Recruiting

  • Investigator Site 23

    Zhuzhou, Hunan, China · Recruiting

  • Investigator Site 37

    Chifeng, Inner Mongolia, China · Recruiting

  • Investigator Site 36

    Hohhot, Inner Mongolia, China · Recruiting

  • Investigator Site 30

    Changzhou, Jiangsu, China · Recruiting

  • Investigator Site 31

    Huai'an, Jiangsu, China · Recruiting

  • Investigator Site 01

    Nanjing, Jiangsu, China · Recruiting

  • Investigator Site 26

    Nantong, Jiangsu, China · Recruiting

  • Investigator Site 27

    Suzhou, Jiangsu, China · Recruiting

  • Investigator Site 29

    Yangzhou, Jiangsu, China · Recruiting

  • Investigator Site 32

    Ganzhou, Jiangxi, China · Recruiting

  • Investigator Site 33

    Nanchang, Jiangxi, China · Recruiting

  • Investigator Site 34

    Shangrao, Jiangxi, China · Recruiting

  • Investigator Site 35

    Shenyang, Liaoning, China · Recruiting

  • Investigator Site 38

    Yinchuan, Ningxia, China · Recruiting

  • Investigator Site 42

    Xi'an, Shaanxi, China · Recruiting

  • Investigator Site 43

    Xi'an, Shaanxi, China · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.